Oktopi AI collaboration for research efficiency
Filed with ASX · · 4 pages · English
Summary by 6ix AI
AdAlta Ltd. has announced a strategic collaboration with Oktopi to enhance its AI capabilities in medicine development. This partnership will provide AdAlta access to the Oktopi Platform, which is designed to improve decision-making and planning in product development. The collaboration is part of AdAlta's broader strategy to integrate AI across its operations, aiming to increase efficiency and success rates in research. AdAlta's Consultant Chief Medical Officer highlighted the potential of this collaboration to rapidly evaluate development plans and optimize resource use. The announcement emphasizes the importance of AI in supporting AdAlta's 'East to West' strategy for drug development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- Second BZDS1901 milestone paid
- Regulatory advisors appointed for BZDS1901
- $2.5m placement
- BZDS1901 manufacturing agreement
- Automated cell therapy manufacturing MoU
Later from AdAlta
- 2 year survival milestone for EW-001 patient
- EW-001 IIT study overall survival update
- BZDS1901 special access scheme launch in China
- Oribiotech deal validates AdAlta manufacturing strategy
- US FDA grants EW-001 pre-IND meeting
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta